Precision Therapeutics secured $33 million in a Series D funding round, led by venture capital firm Bain Capital. Precision will use the proceeds to boost the growth of ChemoFx, a technology that helps identify a type of chemotherapy that is likely to benefit an individual cancer patient, and develop genomics-based products.

Related Summaries